

Yoshihiro Inamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9517930/publications.pdf>

Version: 2024-02-01

88
papers

6,230
citations

147566

31
h-index

74018

75
g-index

93
all docs

93
docs citations

93
times ranked

6135
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
2	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
3	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
4	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
5	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	0.6	228
6	Late effects of blood and marrow transplantation. <i>Haematologica</i> , 2017, 102, 614-625.	1.7	126
7	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
8	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	0.6	93
9	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86
10	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	2.5	83
11	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
12	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	3.2	68
13	Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 919-924.	2.0	66
14	Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1687-1691.	2.0	65
15	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
16	Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012, 119, 2675-2678.	0.6	54
17	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
18	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50

#	ARTICLE	IF	CITATIONS
19	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
20	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	1.3	48
21	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
22	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.4	47
23	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
24	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
25	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 160-166.	0.6	43
26	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2002-2007.	2.0	41
27	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. <i>Haematologica</i> , 2016, 101, 1592-1602.	1.7	41
28	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
29	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	2.0	39
30	Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1102-1107.	2.0	38
31	Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
32	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
33	A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1088-1092.	2.0	35
34	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
35	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	1.7	29
36	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	1.7	29

#	ARTICLE	IF	CITATIONS
37	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29
38	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
39	Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 385-391.	1.7	23
40	Long-Term Outcome after Bone Marrow Transplantation for Aplastic Anemia Using Cyclophosphamide and Total Lymphoid Irradiation as Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 43-49.	2.0	21
41	Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 294-300.	2.0	21
42	Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. <i>International Journal of Hematology</i> , 2008, 87, 451-458.	0.7	20
43	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	0.8	19
44	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	0.6	18
45	Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1901-1913.	2.5	18
46	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1308-1315.	2.0	17
47	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
48	Severe Hypercholesterolemia Associated with Decreased Hepatic Triglyceride Lipase Activity and Pseudohyponatremia in Patients after Allogeneic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2005, 82, 362-366.	0.7	15
49	Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor. <i>International Journal of Hematology</i> , 2006, 83, 356-362.	0.7	15
50	Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2021, 113, 872-876.	0.7	15
51	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	0.6	15
52	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	1.3	14
53	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	2.5	14
54	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
56	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12
57	High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 397-405.	2.5	11
58	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	2.5	11
59	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. <i>Cancer Science</i> , 2022, 113, 2763-2777.	1.7	11
60	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
61	A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 928.e1-928.e7.	0.6	10
62	Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 293-300.	2.0	8
63	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	0.6	8
64	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <i>Blood Advances</i> , 2019, 3, 1750-1760.	2.5	6
65	Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2125-2136.	1.3	6
66	Anterior segment optical coherence tomography evaluation of ocular graft-versus-host disease: a case study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2015, 5, 163-70.	1.1	6
67	The disposable bandage soft contact lenses therapy and anterior segment optical coherence tomography for management of ocular graft-versus-host disease. <i>BMC Ophthalmology</i> , 2021, 21, 271.	0.6	5
68	Usefulness of hematopoietic progenitor cell monitoring to predict autologous peripheral blood stem cell harvest timing: A single-center retrospective study. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103150.	0.5	5
69	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 43-50.	1.3	5
70	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	0.6	5
71	Serologically HLA-DR mismatched Unrelated Donors Might Provide a Valuable Alternative in Allogeneic Transplantation: Experience from a Single Japanese Institution. <i>International Journal of Hematology</i> , 2007, 85, 163-169.	0.7	4
72	Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. <i>International Journal of Hematology</i> , 2022, 115, 158-162.	0.7	4

#	ARTICLE	IF	CITATIONS
73	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	1.3	3
74	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	0.6	3
75	Long-Term Follow-Up Program and Chronic Graft-versus-Host Disease. <i>Journal of Hematopoietic Cell Transplantation</i> , 2017, 6, 84-97.	0.1	2
76	Nausea and vomiting during post-transplantation cyclophosphamide administration. <i>International Journal of Hematology</i> , 2020, 112, 577-583.	0.7	2
77	Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2990-2996.	1.3	2
78	Characterization of readmission after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1335-1340.	1.3	2
79	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2021, , .	2.0	2
80	A Case of Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab. <i>Internal Medicine</i> , 2022, , .	0.3	2
81	JSHCT meeting symposium report: current status and future perspective of chronic graft-versus-host disease. <i>Journal of Hematopoietic Cell Transplantation</i> , 2018, 7, 56-63.	0.1	1
82	Alternative donors: a match for matched sibling donors?. <i>Lancet Haematology</i> , the, 2019, 6, e545-e546.	2.2	1
83	Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2196-2198.	1.3	1
84	Effect of donor type on volume of blood transfusions required after allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2021, 113, 518-529.	0.7	0
85	Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 650-657.	0.8	0
86	Steroid Therapy Increase Only Adenovirus Infection but Not Cytomegalovirus Infection in Dose Dependent Manner after Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5292-5292.	0.6	0
87	HapMap Scanning of Novel Human Minor Histocompatibility Antigens. <i>Blood</i> , 2008, 112, 3908-3908.	0.6	0
88	Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis. <i>Blood</i> , 2014, 124, 4383-4383.	0.6	0